Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1AFAMELANOTIDE[1] Afamelanotide[1] D10511 [1] MC1R 💬[2] Melanogenesis, Neuroactive ligand-receptor interaction 💬[2] 159, 254
2Afamelanotide (16 mg implant)[1] Afamelanotide[1] D10511 [1] MC1R 💬[2] Melanogenesis, Neuroactive ligand-receptor interaction 💬[1] 159
3Ipilimumab[1] Ipilimumab[1] D04603 [1] CTLA4 💬[4] Autoimmune thyroid disease, Cell adhesion molecules, Rheumatoid arthritis, T cell receptor signaling pathway 💬[1] 159
4Isotretinoin[1] Isotretinoin[1] D00348 [2] RARA,
RARB 💬		[8] Acute myeloid leukemia, Estrogen signaling pathway, Gastric cancer, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer 💬[4] 36, 39, 159, 160
5Liposomal T4N5 lotion----[1] 159
6Nivolumab[1] Nivolumab[1] D10316 [1] PDCD1 💬[3] Cell adhesion molecules, PD-L1 expression and PD-1 checkpoint pathway in cancer, T cell receptor signaling pathway 💬[12] 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
7SCENESSE[1] Afamelanotide[1] D10511 [1] MC1R 💬[2] Melanogenesis, Neuroactive ligand-receptor interaction 💬[3] 159, 161, 254
8TRABECTEDINA[1] Trabectedin[1] D06199 --[1] 159
9Trabectedine----[1] 159
10Yondelis[1] Trabectedin[1] D06199 --[1] 159
11YONDELIS 0,25 mg polvo para concentrado para solución para perfusión[1] Trabectedin[1] D06199 --[1] 159
12Yondelis 0.25 mg powder for concentrate for solution for infusion.[1] Trabectedin[1] D06199 --[1] 159
13YONDELIS 1 mg polvo para concentrado para solución para perfusión[1] Trabectedin[1] D06199 --[1] 159
14Yondelis 1 mg powder for concentrate for solution for infusion.[1] Trabectedin[1] D06199 --[1] 159